Osteoprotegerin Polymorphisms in a Mexican Population with Rheumatoid Arthritis and Generalized Osteoporosis: A Preliminary Report
Table 2
Clinical characteristics of study patients.
Characteristic
= 81
Age (years), median (range)
49.9 (21–79)
Menopausal, (%)
43 (53.1)
Weight (kg), median (range)
65.8 (43–94)
BMI, median (range)
26.87 (18–38)
Oral contraceptives use, (%)
41 (50.6)
Current smoker, (%)
17 (21)
Family history of fractures (%)
6 (7.4)
Alcohol consumption 3 or more units/day, (%)
3 (3.37)
Duration of RA (years), median (range)
11.8 (1.5–35)
DAS-28 score, median (range)
3.8 (0–6.7)
Global functional status III-IV, (%)
7 (7.8)
HAQ-DI score, median (range)
0.7 (0–2.8)
Medications
(%)
Glucocorticoid
72 (88.9)
Prednisone dosage (mg/day), median (range)
4.4 (0–10)
Methotrexate
56 (70.9)
Sulfasalazine
39 (49.4)
Chloroquine
27 (34.2)
Azathioprine
25 (31.6)
D-Penicillamine
10 (12.7)
Biologic agents
8 (10.1)
BMD (WHO classification)
(%)
Normal
23 (33.3)
Osteopenia/osteoporosis
46 (66.7)
BMI: body mass index, RA: rheumatoid arthritis, DAS-28: disease activity score, HAQ-DI: health assessment questionnaire-disability index, BMD: bone mineral density, and WHO: World Health Organization.
